Literature DB >> 2754693

Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues.

J J Kaminski1, C Puchalski, D M Solomon, R K Rizvi, D J Conn, A J Elliott, R G Lovey, H Guzik, P J Chiu, J F Long.   

Abstract

Definition of the interrelationship between the conformational characteristics of a series of substituted imidazo[1,2-a]pyridines and their antiulcer activity was investigated by examining the conformational properties of 3-cyano-2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine (1), using a variety of experimental and theoretical methods. The results of these studies was the identification of two distinctly different candidates, designated the "folded" and the "extended" conformation, respectively, to represent the two possible minimum-energy conformations of 1. In order to select the biologically relevant conformer, a group of 3-substituted 2-methylimidazo[1,2-a]pyridines, having either a cis or a trans 2-phenylethenyl substituent at the 8-position were designed as conceptually simple and synthetically accessible semirigid analogues of the respective candidate conformers. Gastric antisecretory activity was found to reside only in the trans isomers (compounds 11, 15, and 17), which mimic the "extended" conformation. This observation led to the construction of 8,9-dihydro-2-methyl-9-phenyl-7H-imidazo[1,2-a]pyrano[2,3-c]pyridi ne-3- acetonitrile (40), a rigid tricyclic analogue that is effectively locked in the "extended" conformation and that exhibited an antiulcer profile comparable to that of prototype 1. These results unequivocally demonstrate that, in accord with expectation for a drug operating at a specific receptor, the conformational characteristics of the molecule have a substantial effect in determining its antiulcer activity. More precisely, it has been demonstrated that it is the "extended" conformation of 1 that represents the "bioactive" form of the drug. These results constitute the basis for a molecular probe that should aid in the investigation of the as yet uncharacterized gastric proton pump enzyme (H+/K+-ATPase), by means of which 1 and its analogues presumably exert their pharmacologic actions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2754693     DOI: 10.1021/jm00128a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  The gastric H,K ATPase as a drug target: past, present, and future.

Authors:  George Sachs; Jai Moo Shin; Olga Vagin; Nils Lambrecht; Iskandar Yakubov; Keith Munson
Journal:  J Clin Gastroenterol       Date:  2007-07       Impact factor: 3.062

2.  One-pot synthesis of 2-phenylimidazo[1,2-α]pyridines from acetophenone, [Bmim]Br(3) and 2-aminopyridine under solvent-free conditions.

Authors:  Zhang-Gao Le; Zong-Bo Xie; Jian-Ping Xu
Journal:  Molecules       Date:  2012-11-09       Impact factor: 4.411

3.  2-Methyl-6-(trifluoro-meth-yl)imidazo[1,2-a]pyridine-3-carbonitrile.

Authors:  Hoong-Kun Fun; Mohd Mustaqim Rosli; D J Madhu Kumar; D Jagadeesh Prasad; G K Nagaraja
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-02-05

4.  An efficient synthesis of new imidazo[1,2-a]pyridine-6-carbohydrazide and pyrido[1,2-a]pyrimidine-7-carbohydrazide derivatives via a five-component cascade reaction.

Authors:  Hajar Hosseini; Mohammad Bayat
Journal:  RSC Adv       Date:  2019-03-05       Impact factor: 4.036

5.  Synthesis of 5-amino-N'-(9H-fluoren-9-ylidene)-8-nitro-7-aryl-1,2,3,7-tetrahydroimidazo[1,2-a]pyridine-6-carbohydrazide derivatives based on heterocyclic ketene aminals.

Authors:  Hajar Hosseini; Mohammad Bayat
Journal:  RSC Adv       Date:  2018-12-11       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.